Literature DB >> 2138514

Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation.

J Goverman1, S M Gomez, K D Segesman, T Hunkapiller, W E Laug, L Hood.   

Abstract

We constructed chimeric receptor chains in which an immunoglobulin heavy chain variable region (VH) from a phosphorylcholine-specific antibody is substituted for T cell receptor (Tcr) alpha and beta V regions. We demonstrate that the VH region joined to either the C alpha or the C beta region can form stable chimeric proteins in EL4 T cells. Both chimeric receptor chains associate with CD3 polypeptides in functional receptor complexes and respond to phosphorylcholine coupled to Sepharose beads. The VH-C alpha chimeric chain associates with the EL4 beta chain, while the VH-C beta chimeric protein appears to form either a homodimer or a heterodimer with the native EL4 beta chain. Thus, functional receptor complexes can be formed using two C beta regions, and the C alpha region may not be required for CD3 association and surface expression of Tcr complexes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138514     DOI: 10.1016/0092-8674(90)90341-b

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  29 in total

Review 1.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Engineered secreted T-cell receptor alpha beta heterodimers.

Authors:  C Grégoire; N Rebaï; F Schweisguth; A Necker; G Mazza; N Auphan; A Millward; A M Schmitt-Verhulst; B Malissen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

Review 3.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

5.  The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Authors:  Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2017-03       Impact factor: 5.987

6.  From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.

Authors:  Zelig Eshhar
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

7.  Major histocompatibility complex independent T cell receptor-antigen interaction: functional analysis using fluorescein derivatives.

Authors:  D J Diamond; P Szalay; D Symer; P Hao; H S Shin; R Z Dintzis; H M Dintzis; E L Reinherz; R F Siliciano
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

Review 8.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

9.  Expression of the TM protein of Rous sarcoma virus in the absence of SU shows that this domain is capable of oligomerization and intracellular transport.

Authors:  D A Einfeld; E Hunter
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

Review 10.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.